Sodium acamprosate and calcium exert additive effects on nucleus accumbens dopamine in the rat

Karin Ademar1 | Louise Adermark1,2 | Bo Söderpalm1,3 | Mia Ericson1

1Addiction Biology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3Beroendekliniken, Sahlgrenska University Hospital, Gothenburg, Sweden

Correspondence
Karin Ademar, Addiction Biology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Box 410, SE 405 30. Gothenburg, Sweden.
Email: karin.ademar@gu.se

Funding information
Swedish Medical Research Council, Grant/Award Numbers: 2018-02814, 2020-00559, 2020-01346, and 2020-02105; Stiftelsen Professor Bror Gadelius minnesfond; Systembolagets alkoholforskningsråd, Grant/Award Number: FO2020-0089.

Abstract
Acamprosate (Campral® – calcium-bis[N-acetylhomotaurinate]) is one of few available pharmacotherapies for individuals suffering from alcohol use disorder. Previously, we suggested that acamprosate reduces ethanol intake by increasing dopamine in the nucleus accumbens (nAc), thereby partly substituting for alcohol's dopamine releasing effect. An experimental study suggested the calcium moiety of acamprosate to be the active component of the drug and to mediate the relapse preventing effect. The aim of the present study was to, by means of reversed in vivo microdialysis, elucidate if the dopamine elevating properties of acamprosate are mediated by N-acetylhomotaurine or by the calcium moiety. Male rats were equipped with a microdialysis probe in the nAc and received acute local treatment with regular acamprosate (CaAcamp 0.5 mM), calcium chloride (CaCl2 0.5 mM), sodium acamprosate (NaAcamp 0.5–1 mM), the glycine receptor (GlyR) antagonist strychnine (Stry 20 μM), or vehicle. In all experiments, extracellular levels of dopamine and taurine were examined. We found that local perfusion with both CaAcamp and CaCl2 increased dopamine levels in a GlyR-dependent manner. NaAcamp did not influence dopamine levels, but concomitant administration with CaCl2 resulted in an additive dopamine output compared to the drugs administrated alone. We also found CaAcamp and the combination of CaCl2 and NaAcamp to increase accumbal taurine levels, suggesting that CaAcamp may act indirectly on GlyRs via taurine release. The present results indicate that both N-acetylhomotaurine and the calcium moiety of acamprosate have dopamine elevating properties within the nAc and that, in this respect, these substances are beneficial in combination.

KEYWORDS
acamprosate, alcohol, calcium, in vivo microdialysis, nucleus accumbens, taurine

INTRODUCTION
Alcohol addiction and the manifested use of alcohol in an abusive way account for a pronounced quantity of the total burden of disease and injury worldwide.1 Alcohol use disorder (AUD) is a chronic relapsing brain disease, involving several neuronal pathways and circuits including the mesolimbic dopamine system, a major part of the brain reward pathway.2,3 Ethanol-induced activation of the mesolimbic dopamine
system increases dopamine levels in the nucleus accumbens (nAc), a phenomenon common to most drugs of abuse and associated with reward and positive reinforcement.4,5

One of the few pharmacotherapies available to treat AUD is acamprosate (calcium-bis[N-acetyltaurinate]; Campral®),6,7 a drug initially found to have an ethanol intake-reducing effect in rat.8 Early clinical studies, with different biological and clinical endpoints, found acamprosate to generate a positive outcome with reduced alcohol intake and relapse frequency in patients with AUD.9,10 Furthermore, a meta-analysis with data originating from both alcohol-dependent men and women demonstrated acamprosate to be beneficial relative to placebo when comparing four efficacy endpoints with no differences in drug response between the sexes.7 In several rodent models, acamprosate treatment was shown to attenuate alcohol seeking behaviour and decrease preference for ethanol,11,12 as well as to reduce the frequency of relapse to high ethanol intake in a dose-dependent manner.13–15 Acamprosate was put on the market in France in 1989,16 that is, more than 30 years ago, and the mechanism of action is still not fully understood. In the development of new molecules targeting cellular or molecular mechanisms related to AUD, it is of importance to gain knowledge of the mechanism of action for existing treatment methods.

Acamprosate is a homotaurine derivative sharing structural analogies with both the γ-aminobutyric acid (GABA) and the endogenous amino acid taurine, a glycine (GlyR) and GABA_A receptor agonist with a number of physiological functions including possessing osmoregulatory properties.6,7 Several hypotheses have been put forward on the mechanism underlying the ethanol-intake reducing effect of acamprosate suggesting a modulatory role on both GABA and glutamate neurotransmission by direct or indirect interaction with GABA_A-, NMDA- and mGluR receptors, respectively.8,18–22 We previously demonstrated that GlyRs in the nAc and nicotinic acetylcholine receptors in the ventral tegmental area also participate in mediating the effects of acamprosate.23,24 In line with others, we found acamprosate to have dopamine elevating properties, following both systemic and local administration in the rat, to a similar degree as previously demonstrated for ethanol25,26 and taurine.27,28 Thus, acamprosate may partially act as a neurochemical substitution for ethanol in its mesolimbic dopamine activating effect. Interestingly, an experimental study suggested that the calcium moiety of the calcium-bis[N-acetyltaurinate] compound is solely responsible for the drug effect on ethanol consumption.29 This conclusion was made because the sodium salt of N-acetyltaurinate failed to reduce excessive alcohol drinking, alcohol-seeking and relapse-drinking behaviour, whereas calcium administration alone was successful. It was further suggested that N-acetyltaurinate lacks a binding site within the central nervous system and is biologically inert.29

As the mechanism of action underlying the effects of acamprosate is still elusive, we aimed to perform an in depth in vivo microdialysis study exploring the acute effects of different salt forms of N-acetyltaurinate and calcium on dopamine output in the nAc. Although it has been suggested that N-acetyltaurinate is biologically inert, we hypothesised that homotaurine may act together with calcium to raise accumbal dopamine levels, and thus, that regular acamprosate could possess two active ingredients. We further postulated that regular acamprosate and calcium would elevate accumbal dopamine levels in a GlyR-dependent manner, thereby resembling the mechanism by which ethanol activates the brain reward system. Because acamprosate shares the same structural backbone as the amino acid taurine, we also aimed to characterise the tentative effects of these drugs on extracellular levels of taurine.

2 MATERIAL AND METHODS

2.1 Animals

Naïve male Wistar rats (Envigo, the Netherlands) weighing 280 to 340 g, corresponding to an age of 9–10 weeks, were used in the experiments. From arrival until the microdialysis probe-placement surgery, the animals were housed in groups of three to four animals in each cage, at constant room temperature (20–22 °C) and humidity (55–65%) and were kept under a regular 12-h light/dark cycle (lights on at 7:00 AM and lights off at 7:00 PM). The animals had access to standard rodent chow and water ad libitum during the entire experiment and were allowed to adapt to the novel environment during 1 week before any experiments were initiated. The study was approved by the Ethics Committee for Animal Experiments, Gothenburg, Sweden.

2.2 Drugs and chemicals

Calcium-bis[N-acetyltaurinate] (CaAcamp) (kindly provided by Merck, Lyon, France), sodium-N-acetyltaurinate (NaAcamp) (TCI, Zwijndrecht, Belgium), CaCl2 (Fisher Scientific, Gothenburg, Sweden) and strychnine hydrochloride (Sigma-Aldrich, Stockholm, Sweden) were dissolved and diluted in Ringer's solution (consisting of [in mmol/l]: 140 NaCl, 1.2 CaCl2, 3.0 KCl and 1.0 MgCl2). CaAcamp, NaAcamp and CaCl2 were all diluted to a concentration of 0.5 mM. NaAcamp was also diluted to an additional concentration of 1 mM, because this concentration equals 0.5 mM CaAcamp with respect to the stoichiometry of CaAcamp (two N-acetyltaurinates to one calcium ion; NaAcamp = one N-acetyltaurinate to one sodium ion). The GlyR antagonist strychnine was diluted to a concentration of 20 μM. All drugs used were administered via reversed microdialysis. Using this type of drug administration, the actual concentration of substance passing over the probe membrane in vivo is difficult to estimate. However, perfusion with 0.5 mM calcium-bis(N-acetyltaurinate) was previously demonstrated to yield approximately the same dopamine output within the nAc as the physiological relevant dose of 200 mg/kg i.p.

2.3 In vivo microdialysis

The microdialysis experiments were performed in awake and freely moving rats (n = 88). Two days prior to the experiment, the rats were anaesthetised by isoflurane (Baxter, Kista, Sweden), mounted into a
stereotaxic instrument (David Kopf Instruments, Lidingö, Sweden) and placed on a heating pad to prevent hypothermia during the surgery. Two holes were drilled for anchoring screws and one for the placement of a custom-made dialysis probe, with an active space of 2 mm, allowing passive diffusion of solutes. The probe was lowered into the nAc core/shell borderline region (A/P: +1.85, M/L: −1.4 mm relative to bregma, D/V: −7.8 relative to dura) and was, together with the anchoring screws, fixed to the scull with Harvard/dental cement (DAB Dental AB, Gothenburg, Sweden). To prevent dehydration, the animals received saline (2 ml 0.9% NaCl s.c.) and were allowed to recover in individual cages before the experiment.

On the day of the microdialysis experiment, the sealed inlet and outlet of the probe were cut open and, via a swivel, connected to a microinjection pump (U-864 Syringe Pump, AgnTho’s, Lidingö Sweden) allowing the animals to move around freely in its home cage. The probes were perfused with Ringer’s solution at a rate of 2 µl/min, and dialysate samples (40 µl) were collected every 20 min during the entire experiment. Two hours prior to baseline sampling began, the rats were perfused with Ringer’s solution to allow for equilibrium. Drugs were administered locally in the nAc after a stable dopamine baseline was obtained, with accepted normal fluctuation of ±10%. Instantly after the experiment, the animals were sacrificed, brains were removed, fixed (Accustain, Sigma-Aldrich, Sweden) and stored (−4°C) until verification of probe placement 5–7 days later. Only rats with a correct probe placement and no visual signs of brain tissue damage were included in the statistical analysis (Figure 1). A total of 10 rats were excluded in this study.

2.4 | Biochemical assays

The dialysate sample was split and analysed for dopamine and taurine separately. Dopamine was separated and detected using two different simultaneously running high-performance liquid chromatography (HPLC) systems with electrochemical detection, as previously described. To identify and quantify the dopamine peak, an external standard containing 3.25 nM of dopamine was used. The dopamine samples were analysed online. In order to avoid degradation of taurine, sodium azide (50% v/v) was added to each individual sample before storage in −20°C. Taurine was detected using an HPLC system with fluorescence detection, as previously described. Identification and quantification of taurine was accomplished by using two external standards containing 0.5–1.0 µM of taurine.

2.5 | Statistical analysis

The content of dopamine and taurine in each sample was expressed as the percentage of the average pre-treatment baseline. From the dialysates collected, the overall drug effect was calculated as the average alteration of dopamine and taurine content after the drug administration (0–180 min or 20–180 min) and was statistically evaluated using two-way analysis of variance (ANOVA) with repeated measures (treatment group × time). One-way ANOVA followed by Tukey’s post hoc analysis was used for statistical evaluation of the area under the curve (AUC). All data are presented as mean ± SEM, and a probability value (p) less than 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Calcium acamprosate elevates dopamine in the nAc but not when perfused in combination with strychnine

In the first set of experiments, we aimed to verify the dopamine elevating effect of acamprosate and the role of GlyRs in mediating this
effect. Animals were pre-treated with either vehicle (Ringer’s solution) or the GlyR antagonist strychnine (20 μM in the perfusate) 20 min before concomitant application of CaAcamp (0.5 mM) via the microdialysate probe. Administration of CaAcamp within the nAc increased the extracellular levels of dopamine as compared to vehicle (Veh) treatment (two-way ANOVA: F₁, 17 = 15.05, p = 0.001, η² = 0.46; time effect F₁, 153 = 4.00, p < 0.001, η² = 0.19; interaction F₁, 153 = 6.20, p < 0.001, η² = 0.26; Figure 2A). However, pre-treatment with strychnine completely blocked the dopamine elevating effect of CaAcamp (two-way ANOVA: F₁, 14 = 0.681, p = 0.423; time effect F₁, 126 = 0.821, p = 0.598; interaction F₁, 126 = 0.759, p = 0.654; Figure 2B).

### 3.2 Calcium chloride elevates dopamine in the nAc, an effect prevented by strychnine

In the next set of experiments, we examined if calcium itself had the capability to increase nAc dopamine. Administration of CaCl₂ (0.5 mM) alone resulted in a modest increase of dopamine compared to vehicle perfused animals (two-way ANOVA: F₁, 14 = 20.31, p < 0.001, η² = 0.59; time effect F₁, 126 = 0.935, p = 0.497; interaction F₁, 126 = 2.00, p = 0.045, η² = 0.12; Figure 3A). In similarity with CaAcamp, the previously observed calcium-induced dopamine elevation was absent in animals pre-treated with strychnine (20 μM; two-way ANOVA: F₁, 14 = 0.592, p = 0.455; time effect F₁, 126 = 1.70, p = 0.096; interaction F₁, 126 = 0.549, p = 0.836; Figure 3B).

## 3.3 Sodium acamprosate administration does not increase nAc dopamine alone but in combination with calcium chloride

In order to evaluate whether the N-acetylhomotaurine part of CaAcam increases nAc dopamine, we explored the effects of the sodium salt of the drug (NaAcamp). Administration of NaAcamp (0.5 mM or 1 mM) did not significantly increase dopamine over time (two-way ANOVA: F₁, 15 = 0.018, p = 0.894, time effect F₁, 135 = 1.55, p = 0.137, interaction F₁, 135 = 0.806.
$p = 0.611; 1 \text{ mM: group effect } F_{1, 19} = 2.15, p = 0.159, \text{ time effect } F_{9, 171} = 0.790, p = 0.626, \text{ interaction } F_{9, 171} = 0.965, p = 0.471; \text{ Figure 4A, B). To further investigate the possible effects of NaAcamp, we explored concomitant administration of CaCl}_2 (0.5 \text{ mM}) \text{ and NaAcamp (1 mM). Perfusion with the combination of the drugs produced a significant elevation of dopamine in comparison to both vehicle-treated animals and to each of the drugs locally perfused alone (one-way ANOVA of AUC } _{20-180 \text{ min}: F (3, 29) = 13.22, p < 0.001, \eta^2 = 0.58; \text{ post hoc analysis: Veh versus CaCl}_2\text{-NaAcamp } p < 0.001, \text{ CaCl}_2 \text{ versus CaCl}_2\text{-NaAcamp } p = 0.023, \text{ NaAcamp versus CaCl}_2\text{-NaAcamp } p < 0.001; \text{ Figure 5A, B).}

3.4 | Acamprosate increases taurine levels in the nAc

As acamprosate is a homotaurine analogue, where the carbon backbone has an acetyl group added at the amino end to facilitate absorption, we wanted to investigate taurine levels in the nAc following the administration of the different salt forms of acamprosate. We also examined the levels of taurine following CaCl}_2 treatment alone and when combined with NaAcamp. The amino acid analysis showed that CaAcamp (0.5 \text{ mM}) has taurine elevating properties compared to vehicle-administrated animals (two-way ANOVA of AUC } _{0-180 \text{ min}: \text{ group effect } F_{1, 18} = 4.16, p = 0.056, \text{ time effect } F_{9, 162} = 2.83, p = 0.004, \eta^2 = 0.14, \text{ interaction } F_{9, 162} = 3.19, p = 0.001, \eta^2 = 0.15; \text{ Figure 6A). Treatment with CaCl}_2 (0.5 \text{ mM}) \text{ or NaAcamp (1 mM) alone did not significantly elevate taurine levels (two-way ANOVA of AUC } _{0-180 \text{ min}: \text{ group effect } F_{1, 14} = 0.794, p = 0.388, \text{ time effect } F_{9, 126} = 0.568, p = 0.821, \eta^2 = 0.14, \text{ interaction } F_{9, 126} = 0.721, p = 0.689; \text{ NaAcamp: group effect } F_{1, 21} = 0.251, p = 0.622, \text{ time effect } F_{9, 189} = 3.07, p = 0.002, \eta^2 = 0.13, \text{ interaction } F_{9, 189} = 1.79, p = 0.073; \text{ Figure 6B, C), whereas the two substances combined increased the accumbal taurine output compared to vehicle treatment (two-way ANOVA of AUC } _{0-180 \text{ min}: \text{ group effect } F_{1, 13} = 8.03, p = 0.014, \eta^2 = 0.38; \text{ time effect } F_{9, 117} = 4.13, p < 0.001, \eta^2 = 0.24; \text{ interaction } F_{9, 117} = 3.85, p < 0.001, \eta^2 = 0.23; \text{ Figure 6D).}

**FIGURE 4** NaAcamp does not increase accumbal dopamine levels alone. Time-course graphs of the nAc dopamine levels following local perfusion with (A) NaAcamp (0.5 \text{ mM}) or vehicle (Ringer’s solution) and (B) NaAcamp (1 mM) or vehicle. Drug administration is indicated by arrows. All data are presented as mean ± SEM. NaAcamp = sodium acamprosate, nAc = nucleus accumbens, Veh = vehicle.

**FIGURE 5** The combination of CaCl}_2 and NaAcamp additively increase dopamine output in the nAc compared to CaCl}_2 and NaAcamp alone. (A) Time-course graphs of the nAc dopamine levels following local perfusion with vehicle (Ringer’s solution), the combination of CaCl}_2 (0.5 \text{ mM}) and NaAcamp (1 mM), as well as following CaCl}_2 (0.5 \text{ mM}) and NaAcamp (1 mM) alone. (B) Area under the curve representing dopamine levels in the nAc following local perfusion with CaCl}_2 (0.5 \text{ mM}), NaAcamp (1 mM), and the combination of CaCl}_2 (0.5 \text{ mM}) and NaAcamp (1 mM) during the time interval 20–180 min. Drug administration is indicated by arrows. All data are presented as mean ± SEM. *p < 0.05, **p < 0.001. AUC = area under the curve, CaCl}_2 = calcium chloride, NaAcamp = sodium acamprosate, nAc = nucleus accumbens, Veh = vehicle.
DISCUSSION

Contradicting the idea that the acamprosate molecule is biologically inactive, the findings presented here show that there is an additive effect produced by calcium and N-acetylhomotaurine on dopamine as well as a potentiated effect on taurine output in the nAc following local drug administration. In addition, this dopamine increase appears to depend on GlyR activation as the acamprosate-induced dopamine elevation was prevented by strychnine pre-treatment. Even though acamprosate previously was demonstrated not to directly interact with α1 subunit containing GlyRs when using a Xenopus oocyte model,33 the drug could interact with other α subunit containing GlyRs or act indirectly through the release of taurine. Regardless, GlyRs appear to be a major participant in the effects of acamprosate as GlyR antagonism also has been shown to reverse the ethanol intake reducing effect of the drug.24

In the search for a mechanism of action for acamprosate, it was suggested that the calcium moiety of acamprosate is solely responsible for the effects of the drug because different forms of calcium mimicked the effects of acamprosate whereas the sodium salt of N-acetylhomotaurine did not.29 By means of in vivo microdialysis, we show in this study that local nAc administration of calcium chloride increases accumbal dopamine. Interestingly, this effect also appears to involve GlyRs, as strychnine prevents the calcium chloride-induced dopamine elevation. When comparing the dopamine increases produced by regular acamprosate and calcium chloride, we found a larger increase by acamprosate indicating a possibility of multiple mechanisms of the compound on dopamine output. Administration of the corresponding sodium salt formulation of acamprosate did not produce a significant alteration of dopamine on a group level, supporting previous studies concluding that the calcium moiety of acamprosate is responsible for the drug’s effect and that N-acetylhomotaurine is biologically inactive.29 Nevertheless, our study exploring nAc dopamine levels demonstrated an enhanced elevation of dopamine following local concomitant administration of calcium chloride and sodium acamprosate. This finding strengthens the idea that calcium and N-acetylhomotaurine exert multiple effects, which may influence dopamine neurotransmission in an additive or even synergistic manner. Hence, N-acetylhomotaurine does not appear to be biologically inert, as suggested by Spanagel and co-workers. It should be noted, however, although we employed the Wistar rat, the Sprague–Dawley strain was used in the former study, a difference which could account for this discrepancy.

Dopamine has been suggested to have a major impact on ethanol consumption, not just as a pharmacological consequence of passive (injections) or active (voluntary intake) ethanol exposure, but the endogenous dopamine tone in the mesolimbic dopamine system appears to differentially drive the individual towards consumption. A spontaneously low dopaminergic tone, or a decreased dopaminergic tone as a consequence of long-term alcohol consumption, appears to be associated with a high voluntary ethanol consumption both in rats and humans.34–36 The increase in dopamine following acamprosate administration has not received much attention when examining the mechanism underlying the anti-alcohol effect of the drug. However, in a previous study, we found a link between the ethanol-intake reducing effect of acamprosate and its ability to increase dopamine.37 Apart from increasing dopamine by itself, acamprosate prevented ethanol from an additional influence on dopamine in the nAc. Conversely, following repeated administration of acamprosate, there appeared to be a tolerance towards the ethanol-intake reducing effect of the drug, and once this phenomenon occurred, acamprosate had also lost its ability to raise nAc dopamine. Whether the decline of effect of

**Figure 6** Extracellular nAc taurine levels are elevated as an effect of administration of acamprosate in different salt formations and combinations. Time-course graphs of the nAc taurine levels following local perfusion with (A) CaAcamp (0.5 mM), (B) CaCl2 (0.5 mM), (C) NaAcamp (1 mM) or (D) the combination of CaCl2 (0.5 mM) and NaAcamp (1 mM) within the nAc. Drug administration is indicated by arrows. All data are presented as mean ± SEM. **p < 0.01, ***p < 0.001.

CaAcamp = calcium acamprosate, CaCl2 = calcium chloride, NaAcamp = sodium acamprosate, nAc = nucleus accumbens, Veh = vehicle
acamprosate following long-term treatment is species specific and only present in the rat, is not known, the dopamine elevating properties of acamprosate may indeed be central to its effect on alcohol consumption. The link between acamprosate and GlyRs may not be direct, but rather indirect as indicated by a previous study. A systemic injection of a very high dose of acamprosate (1 g/kg) was shown to increase nAc taurine, indicating the possibility of an indirect influence of acamprosate on GlyRs. Although previous interpretations included an acamprosate and taurine-induced normalisation of a hyperglutamatergic state, when both acamprosate and taurine were found to block the glutamate increase following ethanol withdrawal, activation of GlyRs may be another or additional effect of the drug. In the present study, we used a lower dose of acamprosate (0.5 mM, corresponding to 200 mg/kg i.p. with regards to influence on nAc dopamine) but were still able to detect a significant increase of taurine. We have previously speculated that acamprosate acts as a neurochemical substitute for ethanol in the mesolimbic dopamine system, because the drug, just as previously shown with ethanol, increases dopamine. Here we thus demonstrate another ability of acamprosate that mimics that of ethanol, the ability to increase taurine. Considering that taurine increases dopamine in the nAc, this further supports the idea that acamprosate may partially act as a substitution for ethanol with regards to dopamine elevation. Indeed, as low dopamine levels may motivate for further ethanol consumption, the acamprosate/taurine-induced activation of GlyRs and the ensuing dopamine elevation may be the underlying reason to decreased ethanol intake. In the present study, we used sodium acamprosate synthesised according to what was previously described. For administration of acamprosate locally in the nAc, we used the same concentration (0.5 mM) as in a previous publication, a concentration equivalent to a physiologically relevant systemic dose of 200 mg/kg i.p. Using calcium chloride, we aimed to obtain approximately the same concentration (0.5 mM) for equivalent amounts of Ca ions. However, as the drugs were administered by reversed microdialysis, the recovery of the compounds could be somewhat different, but we do not estimate this to have a significant impact on the findings presented. Using sodium acamprosate, we perfused two different concentrations (0.5 and 1 mM). The higher concentration equals to the perfused dose of regular acamprosate, as the original acamprosate salt dissociates completely into its constituents following dissolution in a hydrophilic media. The lower concentration contains equivalent amounts of ions (Na versus Ca) with regards to the perfused dose of regular acamprosate and calcium chloride. Furthermore, as taurine is an osmoregulator and is released into the extracellular space upon alterations in the osmotic environment, we considered the difference in osmolarity between the various drug solutions perfused. As no differences with respect to dopamine or taurine output were observed following sodium acamprosate (0.5 mM: dopamine Figure 4A, taurine data not shown; or 1 mM: dopamine Figure 4B, taurine Figure 6C), we chose to only use the higher concentration in combination with calcium chloride to correctly compare 1 mM of sodium acamprosate with 0.5 mM regular acamprosate.

In conclusion, in the present microdialysis study, we show that regular acamprosate increases both dopamine and taurine in the nAc and that the dopamine elevation is GlyR dependent. In contrast to others, we do not find that the calcium moiety of acamprosate is solely responsible for the biological effects of the compound, but instead that the calcium ion and N-acetylhomotaurine act in an additive manner to elevate dopamine in the nAc. The exact mechanism(s) underlying this dual effect of the compound remains to be established, but both increased levels of taurine and activation of GlyRs appear to be important for the dopamine elevating properties of the drug. Whether these additive effects are functionally relevant following systemic administration and with respect to voluntary ethanol intake remains to be established.

ACKNOWLEDGEMENTS
We want to acknowledge Rosita Stomberg for technical support and expertise as well as Esi Domi for statistical aid.

CONFICT OF INTEREST
The authors report no conflict of interest.

AUTHOR’S CONTRIBUTION
M.E. was responsible for the study concept and M.E. and K.A. for the study design. K.A. performed the experiments and performed the statistical analyses. M.E. and K.A. drafted the manuscript. M.E., L.A. and
REFERENCES

1. Rehm J, Gmel GE Sr, Gmel G, et al. The relationship between different dimensions of alcohol use and the burden of disease-an update. Addiction. 2017;112(6):968-1001. doi:10.1111/add.13757

2. Koob GF, Seward NR. The functional output of the mesolimbic dopamine system. Ann N Y Acad Sci. 1988;537(1 The Mesocorti):216-227. doi:10.1111/j.1749-6632.1998.tb42108.x

3. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40(1):191-225. doi:10.1146/annurev.ps.40.020189.001203

4. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274-5278. doi:10.1073/pnas.85.14.5274

5. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci. 1997;9(3):482-497. doi:10.1176/jnp.9.3.482

6. Littletton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90(9):1179-1188. doi:10.1111/j.1360-0443.1995.tb01088.x

7. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36(3):497-508. doi:10.1111/j.1530-0277.2011.01616.x

8. Boismare F, Daoust M, Moore N, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav. 1984;21(5):787-789. doi:10.1016/S0091-3057(84)80002-9

9. Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25(6):613-622. doi:10.1093/oxfordjournals.alcalc.a045057

10. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92(11):1537-1546. doi:10.1111/j.1360-0443.1997.tb02873.x

11. Bachteler D, Economidou D, Danyusz W, Cicciocoppo R, Spanagel R. The effects of acamprosate and naraxemone on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology. 2005;30(6):1104-1110. doi:10.1038/sj.npp.1300657

12. Olive MF, Nannini MA, Qu CJ, Koenig NH, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol. 2002;437(1-2):55-61. doi:10.1016/S0014-2999(02)01272-4

13. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology. 1998;18(2):125-133. doi:10.1016/S0893-133X(97)00130-9

14. Lido HH, Marston H, Ericson M, Soderpalm B. The glycinic reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addict Biol. 2012;17(5):897-907. doi:10.1111/j.1369-1600.2011.00367.x

15. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglsangsberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 1996;305(1-3):39-44. doi:10.1016/0014-2999(96)0174-4

16. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(Suppl 20):42-48.

17. Lambeth IH, Kristensen DM, Holm JB, Mortensen OH. Physiological role of taureine - from organism to organelle. Acta Physiol (Oxf). 2015;213(1):191-212. doi:10.1111/apha.12365

18. al Qatari M, Bouchena O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22(4):810-814. doi:10.1111/j.1530-0277.1998.tb03872.x

19. Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabolotropic glutamate receptors. Alcohol Clin Exp Res. 2002;26(12):1779-1793. doi:10.1111/j.1530-0277.2002.tb02484.x

20. Naasilla M, Hammouni S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22(4):802-809. doi:10.1111/j.1530-0277.1998.tb03871.x

21. Rammes G, Mahal B, Putzke J, et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001;40(6):749-760. doi:10.1016/S0028-3908(01)00008-9

22. Chabernet C, Chretien P, Daoust M, et al. Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. Methods Find Exp Clin Pharmacol. 1988;10(5):311-317.

23. Chau P, Stomberg R, Fagerberg A, Söderpalm B, Ericson M. Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study. Alcohol Clin Exp Res. 2010;34(1):32-38. doi:10.1111/j.1530-0277.2009.01062.x

24. Chau P, Hoifodt-Lido H, Lof E, Soderpalm B, Ericson M. Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate. Alcohol Clin Exp Res. 2010;34(1):39-45. doi:10.1111/j.1530-0277.2009.01063.x

25. Blomqvist O, Ericson M, Engel JA, Soderpalm B. Accumulate dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur J Pharmacol. 1997;334(2-3):149-156. doi:10.1016/S0014-2999(97)01220-X

26. Soderpalm B, Lof E, Ericson M. Mechanistic studies of ethanol's interaction with the mesolimbic dopamine reward system. Pharmacopsychiatry. 2009;42(S 01):587-594. doi:10.1055/s-0029-1220690

27. Ericson M, Molander A, Stomberg R, Soderpalm B. Taurine elevates dopamine levels in the rat nucleus accumbens; antagonism by strychnine. Eur J Neurosci. 2006;23(12):3225-3229. doi:10.1111/j.1460-9586.2006.04868.x

28. Ericson M, Chau P, Clarke RB, Ademar L, Soderpalm B. Rising taurine and ethanol concentrations in nucleus accumbens interact to produce dopamine release after ethanol administration. Addict Biol. 2011;16(3):377-385. doi:10.1111/j.1369-1600.2010.00245.x

29. Spanagel R, Vengeliene V, Jandelet B, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology. 2014;39(4):783-791. doi:10.1038/npp.2013.264

30. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6thed. Amsterdam [u.a.]: Elsevier, Academic Press; 2007.
31. Clarke RB, Adermark L, Chau P, Soderpalm B, Ericson M. Increase in nucleus accumbens dopamine levels following local ethanol administration is not mediated by acetaldehyde. Alcohol Alcohol. 2014;49(5):498-504. doi:10.1093/alcalc/agu047

32. Ulenius L, Andrean A, Adermark L, Soderpalm B, Ericson M. Sub-chronic taurine administration induces behavioral sensitization but does not influence ethanol-induced dopamine release in the nucleus accumbens. Pharmacol Biochem Behav. 2020;188:172831. doi: 10.1016/j.pbb.2019.172831

33. Reilly MT, Lobo IA, McCracken LM, et al. Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008;32(2):188-196. doi:10.1111/j.1530-0277.2007.00569.x

34. Ericson M, Ulenius L, Andren A, Jonsson S, Adermark L, Soderpalm B. Different dopamine tone in ethanol high- and low-consuming Wistar rats. Addict Biol. 2020;25(3):e12761. doi:10.1111/adb.12761

35. Volkow ND, Wang GJ, Begleiter H, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry. 2006;63(9):999-1008. doi:10.1001/archpsyc.63.9.999

36. Volkow ND, Wang GJ, Telang F, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci. 2007;27(46):12700-12706. doi:10.1523/JNEUROSCI.3371-07.2007

37. Chau P, Lido HH, Soderpalm B, Ericson M. Acamprosate’s ethanol intake-reducing effect is associated with its ability to increase dopamine. Pharmacol Biochem Behav. 2018;175:101-107. doi:10.1016/j.pbb.2018.09.009

38. Cowen MS, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence AJ. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol. 2005;10(3):233-242. doi:10.1080/13556210500223132

39. Vengeliene V, Leonardi-Essmann F, Sommer WH, Marston HM, Spangal R. Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. Biol Psychiatry. 2010;68(8):704-711. doi:10.1016/j.biopsych.2010.05.029

40. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol. 2000;60(4):343-362. doi:10.1016/S0301-0082(99)00031-3

41. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 1998;82(2):107-114. doi:10.1016/S0925-4927(98)00016-X

42. Dahchour A, De Witte P. Taurine blocks the glutamate increase in the nucleus accumbens microdialysate of ethanol-dependent rats. Pharmacol Biochem Behav. 2000;65(2):345-350. doi:10.1016/S0921-0924(99)00197-5

43. Soderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. Curr Top Behav Neurosci. 2013;13:127-161. doi:10.1007/7854_2011_170

44. De Witte P, Dahchour A, Quertemont E. Acute and chronic alcohol injections increase taurine in the nucleus accumbens. Alcohol Suppl. 1994;2:229-233.

45. Gongwer MA, Murphy JM, McBride WJ, Lumeng L, Li TK. Regional brain contents of serotonin, dopamine and their metabolites in the selectively bred high- and low-alcohol drinking lines of rats. Alcohol. 1989;6(4):317-320. doi:10.1016/0741-8329(89)90089-X

46. Berrihde MJ. Neuronal calcium signaling. Neuron. 1998;21(1):13-26. doi:10.1016/S0896-6273(00)80510-3

47. Agulhon C, Petravic J, McMullen AB, et al. What is the role of astrocyte calcium in neurophysiology? Neuron. 2008;59(6):932-946. doi:10.1016/j.neuron.2008.09.004

48. Vitarella D, DiRisio DJ, Kimelberg HK, Aschner M. Potassium and taurine release are highly correlated with regulatory volume decrease in neonatal primary rat astrocyte cultures. J Neurochem. 1994;63(3):1143-1149. doi:10.1046/j.1471-4159.1994.63031143.x

49. Solís JM, Herranz AS, Herreras O, Lerma J, del Río RM. Does taurine act as an osmoregulatory substance in the rat brain? Neurosci Lett. 1988;91(1):53-58. doi:10.1016/0304-3940(88)90248-0

How to cite this article: Ademar K, Adermark L, Söderpalm B, Ericson M. Sodium acamprosate and calcium exert additive effects on nucleus accumbens dopamine in the rat. Addiction Biology. 2022;27(5):e13224. doi:10.1111/adb.13224